Sugi Predict

Sugi Predict / Targets / MAPK12

MAPK12

Mitogen-activated protein kinase 12 · P53778 · MAPK12 on Sugi Atlas →

95,813 patent compounds predicted against MAPK12, 65,260 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL67984 SCHEMBL67984 0.89 19/20
SCHEMBL70674 SCHEMBL70674 0.60 19/20
SCHEMBL68380 SCHEMBL68380 0.75 18/20
SCHEMBL69565 SCHEMBL69565 0.68 18/20
SCHEMBL85099 SCHEMBL85099 0.68 18/20
SCHEMBL69086 SCHEMBL69086 0.68 18/20
SCHEMBL68502 SCHEMBL68502 0.67 18/20
SCHEMBL67380 SCHEMBL67380 0.65 18/20
SCHEMBL69184 SCHEMBL69184 0.65 18/20
SCHEMBL67900 SCHEMBL67900 0.64 18/20
Neflamapimod Neflamapimod (SCHEMBL156367) 1.00 17/20
SCHEMBL67023 SCHEMBL67023 0.73 17/20
SCHEMBL68162 SCHEMBL68162 0.71 17/20
SCHEMBL68452 SCHEMBL68452 0.70 17/20
SCHEMBL91495 SCHEMBL91495 0.66 17/20
SCHEMBL68861 SCHEMBL68861 0.64 17/20
SCHEMBL68686 SCHEMBL68686 0.62 17/20
SCHEMBL85106 SCHEMBL85106 0.61 17/20
SCHEMBL67346 SCHEMBL67346 0.60 17/20
SCHEMBL84724 SCHEMBL84724 0.60 17/20

Clinical trials — most relevant to MAPK12 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Anti-oxidative Influence From Pomegranate Tablets on Male Sperm Quality in Couples Undergo Infertility Treatments Due to Male Infertility. PHASE3UNKNOWN
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias PHASE2COMPLETED
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer PHASE2COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer PHASE2UNKNOWN
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome PHASE1/PHASE2RECRUITING
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Safety, Pharmacokinetics (PK) of AKT and MEK Combination PHASE1COMPLETED
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients PHASE1UNKNOWN
ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma PHASE1WITHDRAWN
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma PHASE1COMPLETED
A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors PHASE1COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies PHASE1RECRUITING
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Expression of EPK in Recurrent Miscarriage nanCOMPLETED
p38 Mitogen-Activated Protein Kinase (MAPK) and Steroid Insensitivity in Asthma nanCOMPLETED
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MAPK12 binder may also engage these)

ProteinNameSimilarity
Q63538 — 1.000 Q63538 →
O08911 — 1.000 O08911 →
MAPK13 Mitogen-activated protein kinase 13 0.998 landscape →
Q9Z1B7 — 0.997 Q9Z1B7 →
Q9WTY9 — 0.995 Q9WTY9 →
Q9DGE1 — 0.994 Q9DGE1 →
P70618 — 0.993 P70618 →
G4N374 — 0.993 G4N374 →
MAPK14 Mitogen-activated protein kinase 14 0.992 landscape →
Q9N272 — 0.992 Q9N272 →
O62618 — 0.992 O62618 →
A0A194WDG1 — 0.992 A0A194WDG1 →
O13352 — 0.992 O13352 →
O02812 — 0.992 O02812 →
Q4WQR3 — 0.992 Q4WQR3 →
Q9GRU1 — 0.991 Q9GRU1 →
O42376 — 0.990 O42376 →
P47811 — 0.990 P47811 →
A1DES4 — 0.990 A1DES4 →
O61443 — 0.990 O61443 →
B0Y4X4 — 0.990 B0Y4X4 →
Q9I958 — 0.989 Q9I958 →
Q3T0N5 — 0.989 Q3T0N5 →
O44408 — 0.989 O44408 →
A1CAF0 — 0.988 A1CAF0 →
Q17446 — 0.988 Q17446 →
Q9WUI1 — 0.988 Q9WUI1 →
Q9DGE2 — 0.987 Q9DGE2 →
P54666 — 0.987 P54666 →
Q12126 — 0.987 Q12126 →